LivaNova PLC (NASDAQ:LIVN) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 2nd. Analysts expect the company to announce earnings of $0.76 per share for the quarter. LivaNova PLC has set its FY17 guidance at $3.10-3.30 EPS.
LivaNova PLC (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.19. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. The firm had revenue of $321.40 million for the quarter, compared to the consensus estimate of $315.75 million. The business’s quarterly revenue was up .1% compared to the same quarter last year. On average, analysts expect LivaNova PLC to post $3.3 EPS for the current fiscal year and $3.6 EPS for the next fiscal year.
Shares of LivaNova PLC (LIVN) opened at 73.90 on Wednesday. The firm has a market cap of $3.61 billion, a P/E ratio of 131.96 and a beta of 0.59. LivaNova PLC has a 1-year low of $40.83 and a 1-year high of $75.73. The firm has a 50 day moving average price of $71.88 and a 200 day moving average price of $62.78.
LIVN has been the topic of a number of research analyst reports. WBB Securities cut shares of LivaNova PLC from a “hold” rating to a “sell” rating and set a $50.00 price objective on the stock. in a research report on Tuesday, August 15th. BidaskClub cut shares of LivaNova PLC from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Piper Jaffray Companies reissued an “overweight” rating and set a $75.00 price objective on shares of LivaNova PLC in a research report on Tuesday, September 12th. Needham & Company LLC initiated coverage on shares of LivaNova PLC in a research report on Wednesday, August 23rd. They set a “hold” rating on the stock. Finally, Canaccord Genuity reissued a “hold” rating and set a $71.00 price objective on shares of LivaNova PLC in a research report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $71.50.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $60.76, for a total value of $60,760.00. Following the transaction, the director now owns 58,296 shares of the company’s stock, valued at approximately $3,542,064.96. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 3,000 shares of company stock worth $203,890. 0.28% of the stock is owned by insiders.
About LivaNova PLC
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
What are top analysts saying about LivaNova PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for LivaNova PLC and related companies.